InCarda Therapeutics Appoints Dr. Myles Greenberg as New CEO
Press Release – NEWARK, Calif. – December 10, 2024 – InCarda Therapeutics, a clinical stage biopharmaceutical company developing novel therapeutics for cardiac arrythmias, has announced that Myles Greenberg, MD, MBA will serve as its new president and CEO. Dr. Greenberg joins the company as it advances clinical development of its lead product, an orally inhaled treatment for the rapid conversion of recent-onset and symptomatic atrial fibrillation (AF) to sinus … Continue reading InCarda Therapeutics Appoints Dr. Myles Greenberg as New CEO